<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377335</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-16-12388</org_study_id>
    <nct_id>NCT03377335</nct_id>
  </id_info>
  <brief_title>Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes</brief_title>
  <official_title>Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Palermo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapagliflozin is a member of the sodium-glucose cotransporter-2 (SGLT2) inhibitor class
      antidiabetes agents which produces significant and sustained reductions in glycemic
      parameters in patients with type 2 diabetes (T2DM). However, its non-glycemic effects are
      still largely unknown.

      The investigators will evaluate for the first time the effect of dapagliflozin on multiple
      cardio-metabolic risk markers in one study. So far, no data on the effects of dapagliflozin
      as well as other SGLT-2 inhibitors on subclinical atherosclerosis, endothelial function,
      inflammatory markers, cytokines and atherogenic lipoproteins is available.

      In addition, the investigators will examine microRNAs (miRNAs) implicated in the development
      and progression of atherosclerotic disease. Again, no data is currently available on
      dapaglifozin's as well as other SGLT-2 inhibitors' effects on miRNAs.

      The results of this study will show for the first time the potential multiple, non-glycemic
      effects of dapagliflozin, reducing multiple cardio-metabolic risk markers, which will
      ultimately lead to decreased CV risk.

      In addition, specific mechanisms of the dapagliflozin cardiovascular action will be
      investigated.

      Finally, the results of this study may pave the way for personalized therapy (using the
      results on miRNAs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will perform an open label, two-arms, prospective intervention study using
      dapagliflozin+metformin vs. metformin alone for a period of 6 months in patients with T2DM.

      The research hypothesis is to assess whether dapagliflozin can improve cardio-metabolic
      outcome, reducing subclinical atherosclerosis, endothelial dysfunction and different
      cardio-metabolic markers (including inflammatory markers, cytokines, oxidative stress and
      atherogenic lipoproteins) in patients with T2DM.

      The primary objective is to assess the effects of dapagliflozin on subclinical
      atherosclerosis, as assessed by carotid intima-media thickness (cIMT).

      Primary endpoint: Reduction in cIMT.

      The secondary objective is to assess the effects of dapagliflozin on glycemic parameters
      (fasting plasma glucose (FPG), HbA1c), endothelial dysfunction, oxidative stress, atherogenic
      lipoproteins, inflammatory markers, cytokines and microRNAs (miR-130a, miR-27b, miR-29b and
      miR-210).

      Secondary endpoint: Reduction in glycemic parameters, atherogenic lipoproteins, inflammatory
      markers, oxidative stress and improvements in endothelial function, cytokines and microRNAs
      (miR-130a, miR-27b, miR-29b and miR-210).

      The full data for clinical and biochemical analyses will be collected in the same fashion at
      baseline and after 6 months of therapy.

      Control visits by the telephone calls will be made every 2 months. However, in case of need,
      unplanned visits will be scheduled. Unscheduled visits will be performed in case of
      discontinuation, withdrawal, rescue treatment (including adverse event, episodes of
      hypoglycemia) or at any time during the study in case of patient's need.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 22, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subclinical atherosclerosis</measure>
    <time_frame>Change from baseline to 6 months of the treatment</time_frame>
    <description>To assess the effects of dapagliflozin on subclinical atherosclerosis, as assessed by carotid intima-media thickness (cIMT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial dysfunction</measure>
    <time_frame>Change from baseline to 6 months of the treatment</time_frame>
    <description>To assess the effects of dapagliflozin on endothelial dysfunction through the evaluation of flow mediated dilation (FMD) of the brachial artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>Change from baseline to 6 months of the treatment</time_frame>
    <description>To assess the effects of dapagliflozin on oxidative stress including plasma glutathione, serum lipid hydroperoxides and reactive oxygen species.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atherogenic lipoproteins</measure>
    <time_frame>Change from baseline to 6 months of the treatment</time_frame>
    <description>To assess the effects of dapagliflozin on atherogenic lipoproteins including the analysis of the full spectrum of lipoprotein subclasses by gel electrophoresis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Change from baseline to 6 months of the treatment</time_frame>
    <description>To assess the effects of dapagliflozin on inflammatory markers, including plasma cytokines (pg/ml), that will be assessed using available enzyme-linked immunosorbent assay (ELISA) kits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microRNAs</measure>
    <time_frame>Change from baseline to 6 months of the treatment</time_frame>
    <description>To assess the effects of dapagliflozin on microRNAs. The miRNAs are endogenous 21-25 nucleotides noncoding RNA, and they are regulators of gene expression that post transcriptionally modify cellular responses and function. The miRNAs will be isolated from sera using the mirVana miRNA Isolation Kit (Ambion, Waltham, MA, USA), and then quantified by SYBR Green Real-Time (RT) polymerase chain reaction (PCR).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin (10mg daily) as add-on to metformin (stable doses ranging from 1500 to 3000 mg daily).
The total duration of treatment is 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metformin alone (stable doses ranging from 1500 to 3000 mg daily).
The total duration of treatment is 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).
Number of patients to be randomized: 93
Number of patients expected to complete the study: &gt;87
All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).
Number of patients to be randomized: 93
Number of patients expected to complete the study: &gt;87
All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment.</description>
    <arm_group_label>Metformin alone</arm_group_label>
    <other_name>Glucophage®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women with T2DM;

          -  age &gt;18;

          -  BMI ≥20 kg/m^2;

          -  HbA1c 7.0-9.0 %;

          -  receiving metformin therapy at least 1500 mg/day for at least 8 weeks before
             screening;

          -  plasma triglycerides &lt;400 mg/dL, plasma LDL-cholesterol &lt; 250 mg/dL;

          -  stabile daily dose(s) of hypolipidemic drugs (statins, ezetimibe) for at least 7 weeks
             prior to the day of randomization;

          -  adequately controlled blood pressure (≤140/90 mmHg) to be maintained during the study
             according to Standard of Care;

          -  able to swallow whole tablets.

        Exclusion Criteria:

          -  pregnancy or willingness to became pregnant;

          -  severe liver dysfunction (alanine transaminase (ALT) or aspartate transaminase (AST) ≥
             3 times upper limit of normal);

          -  renal failure with glomerular filtration rate (eGFR) &lt;60 ml/min/1.73m^2;

          -  major cardiovascular event (myocardial infarction, stroke or hospitalization for
             unstable angina and/or transient ischaemic attack) within 12 weeks before screening;

          -  severe infections (such as HIV and HCV);

          -  any malignancy within 5 years before screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, Genovese S, Ceriello A. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016 Dec 3;15(1):162.</citation>
    <PMID>27912784</PMID>
  </reference>
  <reference>
    <citation>Rizzo M, Chandalia M, Patti AM, Di Bartolo V, Rizvi AA, Montalto G, Abate N. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014 Feb 22;13:49. doi: 10.1186/1475-2840-13-49.</citation>
    <PMID>24559258</PMID>
  </reference>
  <reference>
    <citation>Corrado E, Rizzo M, Coppola G, Muratori I, Carella M, Novo S. Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study. Coron Artery Dis. 2008 May;19(3):139-44. doi: 10.1097/MCA.0b013e3282f3fbde.</citation>
    <PMID>18418229</PMID>
  </reference>
  <reference>
    <citation>Salamone F, Galvano F, Marino Gammazza A, Paternostro C, Tibullo D, Bucchieri F, Mangiameli A, Parola M, Bugianesi E, Li Volti G. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig Liver Dis. 2012 Apr;44(4):334-42. doi: 10.1016/j.dld.2011.11.010. Epub 2011 Dec 24. Erratum in: Dig Liver Dis. 2012 Aug;44(8):709. Marino, Antonella [corrected to Marino Gammazza, Antonella].</citation>
    <PMID>22197629</PMID>
  </reference>
  <reference>
    <citation>Rizzo M, Abate N, Chandalia M, Rizvi AA, Giglio RV, Nikolic D, Marino Gammazza A, Barbagallo I, Isenovic ER, Banach M, Montalto G, Li Volti G. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab. 2015 Feb;100(2):603-6. doi: 10.1210/jc.2014-2291. Epub 2014 Nov 13.</citation>
    <PMID>25393640</PMID>
  </reference>
  <reference>
    <citation>Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J. 2010 Jul;31(13):1633-9. doi: 10.1093/eurheartj/ehq181. Epub 2010 Jun 6.</citation>
    <PMID>20525999</PMID>
  </reference>
  <reference>
    <citation>Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos E. &quot;European panel on low density lipoprotein (LDL) subclasses&quot;: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011 Sep;9(5):533-71.</citation>
    <PMID>21595628</PMID>
  </reference>
  <reference>
    <citation>Barbagallo I, Parenti R, Zappalà A, Vanella L, Tibullo D, Pepe F, Onni T, Li Volti G. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma. Acta Histochem. 2015 Oct;117(8):705-11. doi: 10.1016/j.acthis.2015.09.005. Epub 2015 Oct 19.</citation>
    <PMID>26493719</PMID>
  </reference>
  <reference>
    <citation>Cengiz M, Yavuzer S, Kılıçkıran Avcı B, Yürüyen M, Yavuzer H, Dikici SA, Karataş ÖF, Özen M, Uzun H, Öngen Z. Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clin Exp Hypertens. 2015;37(8):643-9. doi: 10.3109/10641963.2015.1036064. Epub 2015 Jun 26.</citation>
    <PMID>26114349</PMID>
  </reference>
  <reference>
    <citation>Tziomalos K, Athyros VG, Karagiannis A. Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs. Curr Vasc Pharmacol. 2016;14(2):208-10.</citation>
    <PMID>26864445</PMID>
  </reference>
  <reference>
    <citation>Signorelli SS, Volsi GL, Pitruzzella A, Fiore V, Mangiafico M, Vanella L, Parenti R, Rizzo M, Volti GL. Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress. Angiology. 2016 Nov;67(10):945-950. doi: 10.1177/0003319716638242. Epub 2016 Jul 11.</citation>
    <PMID>26980776</PMID>
  </reference>
  <reference>
    <citation>Peng H, Zhong M, Zhao W, Wang C, Zhang J, Liu X, Li Y, Paudel SD, Wang Q, Lou T. Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients. PLoS One. 2013 Dec 9;8(12):e82607. doi: 10.1371/journal.pone.0082607. eCollection 2013.</citation>
    <PMID>24349318</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Palermo</investigator_affiliation>
    <investigator_full_name>Manfredi Rizzo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Carotid intima-media thickness</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Atherogenic lipoproteins</keyword>
  <keyword>Inflammatory markers</keyword>
  <keyword>microRNAs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

